Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors

International Clinical Psychopharmacology

Volumn 22, Issue 3, 2007, Pages 137-143

  Smits, Kim ^a   Smits, Luc ^a   Peeters, Frenk ^a   Schouten, Jan ^a   Janssen, Rob ^a   Smeets, Hubert ^a   Os, Jim Van ^a   Prins, Martin ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adverse events; Depression; Pharmacogenetics; Selective serotonin reuptake inhibitors; Serotonin transporter polymorphisms

Indexed keywords

SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; ASTHENIA; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; EJACULATION DISORDER; FATIGUE; FEMALE; GENERAL PRACTITIONER; GENOTYPE; HEADACHE; HUMAN; INSOMNIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FAMILY PRACTICE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; RISK FACTORS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 34147114969     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328014822a     Document Type: Article

References (41)

1. Anderson IA (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36.
2. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23:563-567.
3. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, et al. (2002). Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 288:1403-1409.
4. Cardon LR, Palmer LJ (2003). Population stratification and spurious allelic association. Lancet 361:598-604.
5. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386-389.
6. Cederberg J, Knight S, Svenson S, Melhus H (2004). Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report. BMC Psychiatry 4:36.
7. Ferguson JM (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3:22-27.
8. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmacher T (2004). Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res 38:485-489.
9. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. (2002). A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111:235.
10. Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B (2005). The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 62:529-535.
11. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. (2000). Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219.
12. Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT (2005). Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 133:110-115.
13. Levinson DF (2006). The genetics of depression: a review. Biol Psychiatry 60:84-92.
14. Linden RD, Wilcox CS, Heiser JF, Cavanaugh E, Wisselink PG (1994). Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives? Psychopharmacol Bull 30:151-156.
15. Lotrich FE, Pollock BG (2004). Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 14:121-129.
16. Lotrich FE, Pollock BG, Ferrell RE (2001). Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics 1:153-164.
17. Mandelli L, Serretti A, Marino E, Pirovano A, Calati R, Colombo C (2006). Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int J Neuropsychopharmacol. Epud ahead of print: 1-11.
18. Masand PS (2003). Tolerability and adherence issues in antidepressant therapy. Clin Ther 25:2289-2304.
19. Meijer WE, Heerdink ER, van Eijk JT, Leufkens HG (2002). Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf 11:655-662.
20. Metsemakers JF, Hoppener P, Knottnerus JA, Kocken RJ, Limonard CB (1992). Computerized health information in The Netherlands: a registration network of family practices. Br J Gen Pract 42:102-106.
21. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL (2001). The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 58:539-544.
22. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:1830-1835.
23. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF (2004). Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61:1163-1169.
24. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, et al. (1996). Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347:731-733.
25. Park JW, Kim JS, Lee HK, Kim YI, Lee KS (2004). Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache 44:1005-1009.
26. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, et al. (2003). Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54:879-883.
27. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
28. Popp J, Leucht S, Heres S, Steimer W (2006). Serotonin transporter polymorphisms and side effects in antidepressant therapy-a pilot study. Pharmacogenomics 7:159-166.
29. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Mac Hobby H, et al. (2002). Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol Psychiatry 51:723-732.
30. Rothman K, Greenland S (1998). Modern epidemiology. (2nd ed.) Philadelphia: Lipincott, Williams & Wilkins.
31. Serretti A, Cusin C, Rausch JL, Bondy B, Smeraldi E (2006). Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 145:61-65.
32. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
33. Smits KM, Smits LJ, Schouten JS, Peeters FP, Smeets HJ, van Os J, Prins MH (2004). Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 9:433-441.
34. Stahl SM (1998). Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215-235.
35. Surtees PG, Wainwright NW, Willis-Owen SA, Luben R, Day NE, Flint J (2006). Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry 59:224-229.
36. Wacholder S, Rothman N, Caporaso N (2000). Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 92:1151-1158.
37. Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, et al. (2006). Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 188:210-215.
38. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386.
39. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115-1119.
40. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107.
41. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323-330.